These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 10197832)
1. Long-term use of sedative and hypnotic medication. Dunner DL Arch Gen Psychiatry; 1999 Apr; 56(4):355. PubMed ID: 10197832 [No Abstract] [Full Text] [Related]
2. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830 [No Abstract] [Full Text] [Related]
3. The report by the Institute of Medicine and postmarketing surveillance. Klein DF Arch Gen Psychiatry; 1999 Apr; 56(4):353-4. PubMed ID: 10197831 [No Abstract] [Full Text] [Related]
4. [Halcion (triazolam) in the treatment of insomnia]. Muzychenko AP; Prokudin VN; Bogdan AN Ter Arkh; 1997; 69(1):65-8. PubMed ID: 9163057 [TBL] [Abstract][Full Text] [Related]
5. The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist. O'Malley P Clin Nurse Spec; 2007; 21(4):188-90. PubMed ID: 17622806 [No Abstract] [Full Text] [Related]
6. Triazolam and diphenhydramine effects on seizure duration in depressed patients receiving ECT. Guthrie SK; Sung JC; Goodson J; Grunhaus L; Tandon R Convuls Ther; 1996 Dec; 12(4):261-5. PubMed ID: 9034702 [No Abstract] [Full Text] [Related]
7. Zolpidem and driving impairment--identifying persons at risk. Farkas RH; Unger EF; Temple R N Engl J Med; 2013 Aug; 369(8):689-91. PubMed ID: 23923991 [No Abstract] [Full Text] [Related]
8. Lost in transmission--FDA drug information that never reaches clinicians. Schwartz LM; Woloshin S N Engl J Med; 2009 Oct; 361(18):1717-20. PubMed ID: 19846841 [No Abstract] [Full Text] [Related]
10. The FDA in 2006: reasons for optimism. Chabner BA; Roberts TG Oncologist; 2007 Mar; 12(3):247-9. PubMed ID: 17405888 [No Abstract] [Full Text] [Related]
11. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. Jonas JM; Coleman BS; Sheridan AQ; Kalinske RW J Clin Psychiatry; 1992 Dec; 53 Suppl():19-31; discussion 32-3. PubMed ID: 1336776 [TBL] [Abstract][Full Text] [Related]
12. Congress responds to the IOM drug safety report--in full. Psaty BM; Korn D JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202 [No Abstract] [Full Text] [Related]
14. Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. McCall WV; Benca RM; Rosenquist PB; Riley MA; McCloud L; Newman JC; Case D; Rumble M; Krystal AD Am J Psychiatry; 2017 Jan; 174(1):18-25. PubMed ID: 27609243 [TBL] [Abstract][Full Text] [Related]
15. FDA-Approved Drugs to Treat Sleep Disorders. J Psychosoc Nurs Ment Health Serv; 2019 Oct; 57(10):5-6. PubMed ID: 31573658 [No Abstract] [Full Text] [Related]
16. The pit (of sleeplessness) and the pendulum (of regulation). Bliwise DL Sleep Med; 2010 Jan; 11(1):7-8. PubMed ID: 19945339 [No Abstract] [Full Text] [Related]
17. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Wysowski DK; Baum C Arch Intern Med; 1991 Sep; 151(9):1779-83. PubMed ID: 1888243 [TBL] [Abstract][Full Text] [Related]
18. Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf MB J Clin Psychiatry; 1993 Jan; 54(1):33-8. PubMed ID: 8428895 [TBL] [Abstract][Full Text] [Related]
19. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. Psaty BM; Meslin EM; Breckenridge A JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032 [No Abstract] [Full Text] [Related]
20. The beneficial and adverse effects of hypnotics. Balter MB; Uhlenhuth EH J Clin Psychiatry; 1991 Jul; 52 Suppl():16-23. PubMed ID: 2071567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]